Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Research

Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination

Alex Dulovic1, Monika Strengert1, Gema Morillas Ramos1, Matthias Becker, Johanna Griesbaum, Daniel Junker, Karsten Lürken, Andrea Beigel, Eike Wrenger, Gerhard Lonnemann, Anne Cossmann, Metodi V. Stankov, Alexandra Dopfer-Jablonka, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Gérard Krause2Comments to Author , Nicole Schneiderhan-Marra2Comments to Author , and Georg M.N. Behrens2Comments to Author 
Author affiliations: University of Tübingen Natural and Medical Sciences Institute, Reutlingen, Germany (A. Dulovic, M. Becker, J. Griesbaum, D. Junker, P.D. Kaiser, B. Traenkle, U. Rothbauer, N. Schneiderhan-Marra); Helmholtz Centre for Infection Research, Braunschweig, Germany (M. Strengert, G. Krause); TWINCORE GmbH Centre for Experimental and Clinical Infection Research, Hannover, Germany (M. Strengert, G. Krause); Hannover Medical School, Hannover (G. Morillas Ramos, A. Cossmann, M.V. Stankov, A. Dopfer-Jablonka, G.M.N. Behrens); Dialysis Centre Eickenhof, Langenhagen, Germany (K. Lürken, A. Beigel, E. Wrenger, G. Lonnemann); German Centre for Infection Research, Hannover–Braunschweig, Germany (A. Dopfer-Jablonka, G. Krause, G.M.N. Behrens); University of Tübingen Pharmaceutical Biotechnology, Tübingen (U. Rothbauer); Centre for Individualized Infection Medicine, Hannover (G.M.N. Behrens)

Main Article

Table

Characteristics of participants in a study of immune response against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination*

Characteristic Nondialysis control group Hemodialysis group p value for difference between groups
No. (%) patients
 23 (100)
 76 (100)
 NA
Median age, y (IQR)
 55 (14)
 70.5 (18.25)
 2.78 × 10−9
Sex 1.01 × 10−2†
M 6 (26.09) 43 (56.58)
F
 17 (73.91)
 33 (43.42)
Median days since start of hemodialysis (IQR)
 NA
 1,337 (1,686.5)
 NA
Using immunosuppressive medication
 0
 10 (13.16)
 6.77 × 10−2
Underlying condition
Obesity, BMI >30‡ 4 (17.39) 16 (21.05) 8.68 × 10−1
Diabetes mellitus 0 19 (25) 7.30 × 10−3
Cardiovascular disease 0 35 (46.05) 2.93 × 10−5

*Values are no. (%) except as indicated. Percentages are for total group. BMI, body mass index; IQR, interquartile range; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p value reflects difference in male-to-female ratios between the two groups, not differences explicitly for either male or female persons. ‡BMI for 1 person was not known.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: December 28, 2021
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external